The effect of nebulised iso-osmolar, preservative free, but acidic salbutamol solution was studied in 34 acutely wheezing infants aged 1-17 months. Transcutaneous oxygen pressure (TcPO2) and oxygen saturation (So2) fell significantly during the first five minutes after nebulisation with further deterioration at 15-20 minutes. Ten of these infants were followed up for another two hours and showed slight improvement. Even after the second hour TcPo2 had not reached baseline values. Three months later the response to salbutamol and a placebo of equal acidity (pH 3.9) was studied in 11 infants from the same group, now free of symptoms. Lung function tests were included and showed no significant changes in specific conductance and volume corrected maximum expiratory flows (Vmax at functional residual capacity/thoracic gas volume). However, hypoxaemia occurred after the acidic placebo with a significant drop of TcPo2 (mean 0-9 kPa); So2 decreased similarily but this did not reach significance. After salbutamol there was a further significant deterioration of mean TcPo2 (1-4 kPa) and of So2. These results show that beside a possible pharmacological effect of salbutamol the acidity of the aerosol also induces hypoxaemia in infants. Nebulised salbutamol has been shown to cause hypoxaemia in acutely wheezy infants.' Similarly, several lung function parameters of wheezy infants were found to deteriorate after nebulisation of salbutamol,2" but their relation to hypoxaemia has not been proved. The mechanisms of hypoxaemia after inhalation of salbutamol are still unclear. An increase of ventilation-perfusion mismatch could be caused by raised pulmonary perfusion5 as well as reduced airway smooth muscle tone leading to higher airway compression during forced expiration.2 3 Also the physical properties of the aerosol including acidity and osmolarity4 or the content of preservative6 may be responsible for the observed negative effects. Furthermore hypoxaemia could be explained by a rise in oxygen consumption, which may be induced by salbutamol7 or just by the sedation (chloral hydrate),8 which is often used to perform the lung function tests.
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The clinically important observation of hypoxaemia after nebulisation of salbutamol has so far been made in only five wheezy infants, who all were sedated with chloral hydrate. The observation period was no longer than 20 minutes and oxygen pressure did not return to baseline during that time period. The placebo used was physiological saline; the salbutamol solution however was acidic.' 9 We therefore performed two test series to obtain further information. In both tests transcutaneous oxygen pressure (TcPo2) and saturation (So2) were measured after nebulisation of a preservative free and iso-osmolar salbutamol solution. In the first test acutely wheezing infants were studied without sedation over a period of 2-5 hours. From these, some infants could be re-examined when free of symptoms with additional lung function tests before and after salbutamol and placebo of equal acidity. After measurements had been obtained from 15 patients, we decided to extend the observation period and 10 patients could be follow up to 2-5 hours. The means from 60-80 minutes and 120-140 minutes after nebulisation were recorded.
Patients and methods
Informed consent was obtained from parents of 11/34 infants to participate in a second test about three months later when the infants were without clinical symptoms and free of infection. Their mean age then was 9-5 months (range 6-14 months). They received 80-100 mg/kg chloral hydrate orally. When fig 3) . However, TCP02 was still significantly different from baseline (p<0-013). salbutamol TcPo2 decreased even further to 8-6 kPa, significantly different from baseline values (p<0012) and from both readings after placebo (p<0-018 and p<0012). Smaller changes could be observed with So2 (table 3) , the only significant difference occurring between before and after salbutamol (p<0-012). we have shown persistence of low values for oxygen pressure up to two hours thereafter. Our patients were not sedated. We also used an isoosmolar solution, and although an increase in osmolarity during nebulisation has been described,4 neither bronchoconstriction nor hypoxaemia' has been shown after physiological saline. Our solution did not contain preservatives also known to evoke bronchoconstric- 6 13 tion.
The salbutamol solution we used, however, was acidic. For the lung function tests we therefore decided to use a placebo of equal acidity, which to our knowledge has not been reported so far. Citric acid has been nebulised to dogs inducing airway obstruction with two mechanisms being suggested by the authors: reflex bronchoconstriction after a nebulisation period of two minutes and a mediator induced bronchoconstriction after nebulisation for five minutes. ' and Vmax FRC3 has been reported after an acidic salbutamol solution. In the present study we could not find significant deterioration in airway resistance, specific conductance or Vmax FRC/TGV after placebo or salbutamol. A possible explanation may be that we measured lung function between seven and 13 minutes after nebulisation to avoid disturbance of oxygen measurements, so we might have missed an initial reaction of airway mechanics. However, we did notice a significant drop of TcPo2 after nebulisation of the acidic placebo which did not fully recover by 20 minutes.
From these results the question arises whether hypoxaemia after salbutamol could be a preventable side effect not related to the drug itself but to acidity. We did not nebulise a neutral salbutamol solution and therefore cannot answer this question definitively. Although severity and duration of hypoxaemia were more pronounced after salbutamol than after placebo, this could be explained by an additive effect of nebulising an acidic aerosol twice. However, in our first test the fall in TcPo2 related well to the rise of heart rate which persisted for more than one hour after salbutamol. This could indicate that hypoxaemia was due to a systemic effect of salbutamol. Inhaled as well as intravenously administered salbutamol may cause ventilationperfusion mismatch, which could result from an increase in pulmonary perfusion into relatively less ventilated areas.5 20 Furthermore, there has been evidence for increased oxygen consumption after salbutamol in monkeys7 and adult asthmatics,5 which offers another explanation for the observed hypoxaemia.
As we did not notice any significant effects of salbutamol on lung function, we cannot confirm the findings of other authors that in infants reduction in smooth muscle tone might render the airways less capable of supporting high flow rates during forced expiration.2 21
In conclusion we believe that salbutamol does have a pharmacological effect causing hypoxaemia. What we could prove is that acidity itself induces hypoxaemia and may therefore enhance the negative effects of salbutamol. We therefore recommend that nebuliser solutions should be neutralised as far as possible and more information concerning the different properties of the aerosols be made available.
